Hiv was Gsk’s largest revenue line in fiscal 2025, bringing in $7.69B of $32.67B (24%).
| Products and services [axis] | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2020 | FY 2021 | FY 2022 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| General Medicines | — | — | ||||||
| Established Pharmaceuticals | — | — | ||||||
| Vaccines | — | — | ||||||
| Specialty Medicines | — | — | ||||||
| Respiratory | $6.55B | $7.07B | ||||||
| Hiv | $5.75B | $7.69B | ||||||
| Respiratory, Immunology & Inflammation | — | $3.81B | ||||||
| Other General Medicines | $3.57B | $2.97B | ||||||
| Wellness | — | — | ||||||
| Established Vaccines | $3.09B | $3.12B | ||||||
| Respiratory/Immunology & Other | $2.61B | — | ||||||
| Oral Care | — | — | ||||||
| Shingles | $2.96B | $3.56B | ||||||
| Pandemic | $2.31B | — | ||||||
| Pain Relief | — | — | ||||||
| Digestive Health & Other | — | — | ||||||
| Brands Divested | — | — | ||||||
| Respiratory Health | — | — | ||||||
| Meningitis | $1.12B | $1.58B | ||||||
| Oncology | $602.00M | $1.98B | ||||||
| Nutrition | — | — | ||||||
| Rsv (Arexvy) | — | $593.00M | ||||||
| Skin Health | — | — | ||||||
| Influenza | $714.00M | $303.00M | ||||||
| Immuno Inflammation | — | — | ||||||
| Pandemic Vaccines | $64.00M | — | ||||||
| Vitamins Minerals & Supplements | — | — | ||||||
| Total | $29.32B | $32.67B |
Gsk brought in $32.67B from its 10 revenue lines in fiscal 2025, the year ended December 31, 2025. Gsk regrouped these revenue lines after fiscal 2022, so the total does not compare directly with that year's $29.32B. Hiv was the largest at $7.69B (23.5%), ahead of Respiratory at $7.07B (21.6%) and Respiratory, Immunology & Inflammation at $3.81B (11.7%). The other seven revenue lines brought in $14.10B combined.
Compared with fiscal 2022, the previous year with figures, Oncology grew fastest, up 228.4% to $1.98B, while Other General Medicines fell the most, down 16.9% to $2.97B.
Gsk began breaking out Respiratory, Immunology & Inflammation in fiscal 2025 and Rsv (Arexvy) in fiscal 2025. Gsk stopped reporting Respiratory/Immunology & Other ($2.61B in fiscal 2022), Pandemic ($2.31B in fiscal 2022) and Pandemic Vaccines ($64.00M in fiscal 2022) as separate revenue lines.
Us was Gsk’s largest region in fiscal 2025, bringing in $16.86B of $32.67B (52%).
| Geography | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rest Of World | $14.09B | — | — | — | |||||||
| Rest Of World. | — | — | — | — | |||||||
| Us | $14.54B | $15.82B | $16.38B | $16.86B | |||||||
| International | — | $7.94B | $8.33B | $8.28B | |||||||
| Europe | — | $5.87B | $5.96B | $6.85B | |||||||
| Uk Current Year Charge | $695.00M | $693.00M | $708.00M | $683.00M | |||||||
| Uk | — | — | — | — | |||||||
| Total | $29.32B | $30.33B | $31.38B | $32.67B |
Gsk brought in $32.67B from its four regions in fiscal 2025, the year ended December 31, 2025. That was up 4.1% from $31.38B in fiscal 2024. Us was the largest at $16.86B (51.6%), ahead of International at $8.28B (25.3%) and Europe at $6.85B (21.0%). The remaining region, Uk Current Year Charge, brought in $683.00M.
Compared with fiscal 2024, Europe grew fastest, up 15.0% to $6.85B, while Uk Current Year Charge fell the most, down 3.5% to $683.00M.
Gsk began breaking out Europe in fiscal 2023, when it brought in $5.87B. Gsk stopped reporting Rest Of World as a separate region after fiscal 2022, when it brought in $14.09B.
Gsk (GSK) reports its revenue by products and services [axis] and by geography. In fiscal 2025, Hiv was its largest revenue line, bringing in $7.69B (23.5% of the total), followed by Respiratory at $7.07B (21.6%).
Hiv was Gsk's largest revenue line in fiscal 2025, bringing in $7.69B, or 23.5% of the $32.67B total across its 10 revenue lines.
Us was Gsk's largest region in fiscal 2025, bringing in $16.86B, or 51.6% of the $32.67B total across its four regions.
Among Gsk's regions that make up at least 2% of revenue, Europe grew fastest in fiscal 2025, up 15.0% from $5.96B to $6.85B.
Every figure comes from Gsk's annual financial filings, as reported. Each line keeps the name Gsk gives it, and years follow its fiscal calendar.
Gsk's revenue by products and services [axis] goes back to fiscal 2015, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.